TY - JOUR
T1 - Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients
AU - Shah, Pali
AU - Lowery, Erin
AU - Chaparro, Cecilia
AU - Visner, Gary
AU - Hempstead, Sarah E.
AU - Abraham, James
AU - Bhakta, Zubin
AU - Carroll, Maggie
AU - Christon, Lillian
AU - Danziger-Isakov, Lara
AU - Diamond, Joshua M.
AU - Lease, Erika
AU - Leonard, Jessica
AU - Litvin, Marina
AU - Poole, Ray
AU - Vlahos, Fanny
AU - Werchan, Chelsey
AU - Murray, Michelle A.
AU - Tallarico, Erin
AU - Faro, Albert
AU - Pilewski, Joseph M.
AU - Hachem, Ramsey R.
N1 - Funding Information:
Dr. Lease received grant funding from the Cystic Fibrosis Foundation. Dr. Danziger-Isakov has received grant funding from Merck, Astellas, Ansun Biopharma, and Takeda, and has received funding for service on an advisory board or consulting fees from GSK, Merck, and Takeda. Dr. Hachem has received grant funding from Bristol Myers Squibb and Mallinckrodt, and has received funding for service on an advisory board or speaker fees from Transmedics, CareDx, Theravance, and Vectura. The remaining authors have no conflicts of interest to disclose.
Funding Information:
Work to develop these consensus statements and write this manuscript was funded and supported by the Cystic Fibrosis Foundation .
Publisher Copyright:
© 2021 International Society for Heart and Lung Transplantation
PY - 2021/7
Y1 - 2021/7
N2 - Cystic fibrosis (CF) is the indication for transplantation in approximately 15% of recipients worldwide, and Cystic Fibrosis Lung Transplant Recipients (CFLTRs) have excellent long-term outcomes. Yet, CFLTRs have unique comorbidities that require specialized care. The objective of this document is to provide recommendations to CF and lung transplant clinicians for the management of perioperative and underlying comorbidities of CFLTRs and the impact of transplantation on these comorbidities. The Cystic Fibrosis Foundation (CFF) organized a multidisciplinary committee to develop CF Lung Transplant Clinical Care Recommendations. Three workgroups were formed to develop focused questions. Following a literature search, consensus recommendations were developed by the committee members based on literature review, committee experience and iterative revisions, and in response to public comment. The committee formulated 32 recommendation statements in the topics related to infectious disease, endocrine, gastroenterology, pharmacology, mental health and family planning. Broadly, the committee recommends close coordination of care between the lung transplant team, the cystic fibrosis care center, and specialists in other disciplines with experience in the care of CF and lung transplant recipients. These consensus statements will help lung transplant providers care for CFLTRs in order to improve post-transplant outcomes in this population.
AB - Cystic fibrosis (CF) is the indication for transplantation in approximately 15% of recipients worldwide, and Cystic Fibrosis Lung Transplant Recipients (CFLTRs) have excellent long-term outcomes. Yet, CFLTRs have unique comorbidities that require specialized care. The objective of this document is to provide recommendations to CF and lung transplant clinicians for the management of perioperative and underlying comorbidities of CFLTRs and the impact of transplantation on these comorbidities. The Cystic Fibrosis Foundation (CFF) organized a multidisciplinary committee to develop CF Lung Transplant Clinical Care Recommendations. Three workgroups were formed to develop focused questions. Following a literature search, consensus recommendations were developed by the committee members based on literature review, committee experience and iterative revisions, and in response to public comment. The committee formulated 32 recommendation statements in the topics related to infectious disease, endocrine, gastroenterology, pharmacology, mental health and family planning. Broadly, the committee recommends close coordination of care between the lung transplant team, the cystic fibrosis care center, and specialists in other disciplines with experience in the care of CF and lung transplant recipients. These consensus statements will help lung transplant providers care for CFLTRs in order to improve post-transplant outcomes in this population.
KW - cystic fibrosis
KW - infection
KW - lung transplantation
KW - mental health
KW - rejection
KW - shared care
UR - http://www.scopus.com/inward/record.url?scp=85108230416&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2021.04.011
DO - 10.1016/j.healun.2021.04.011
M3 - Editorial
C2 - 34103223
AN - SCOPUS:85108230416
VL - 40
SP - 539
EP - 556
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
SN - 1053-2498
IS - 7
ER -